Billings Clinic
Especially For:

Clinical Trials

Title   GI-Colorectal Metastatic Second Line
Description   Protocol I4T-MD-JVBB(a)- A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
IRB Number   20101327
Category   Gastrointestinal
Inclusion/Notes   1. Patients must have progressed radiographically within 6 months of completing first line therapy, progressed radiographically 6 months after last dose of first line therapy, or discontinued part or all of first line therapy and have progressed within 6 months following.
2. Patient cannot have received any other combination of chemotherapy besides bevacizumab, oxaliplatin, and a fluoropyrimidine.
3. KRAS status must be known prior to enrollment
Status   Open
Start Date   12/01/2010
Principal Investigator (PI)   Jorge Nieva, MD
Contact Name   Tricia Montgomery, BSN RN
Contact Email   tmontgomery@billingsclinic.org
Phone   (406) 435-7483
Fax   (406) 435-7489
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.